SGLT2 inhibition via empagliflozin improves endothelial function and reduces mitochondrial oxidative stress: insights from frail hypertensive and diabetic patients
P Mone, F Varzideh, SS Jankauskas, A Pansini… - …, 2022 - Am Heart Assoc
Background: Frailty is a multidimensional condition often diagnosed in older adults with
hypertension and diabetes, and both these conditions are associated with endothelial …
hypertension and diabetes, and both these conditions are associated with endothelial …
[HTML][HTML] The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
S Steven, M Oelze, A Hanf, S Kröller-Schön, F Kashani… - Redox biology, 2017 - Elsevier
Hyperglycemia associated with inflammation and oxidative stress is a major cause of
vascular dysfunction and cardiovascular disease in diabetes. Recent data reports that a …
vascular dysfunction and cardiovascular disease in diabetes. Recent data reports that a …
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
B Lin, N Koibuchi, Y Hasegawa, D Sueta… - Cardiovascular …, 2014 - Springer
Background There has been uncertainty regarding the benefit of glycemic control with
antidiabetic agents in prevention of diabetic macrovascular disease. Further development of …
antidiabetic agents in prevention of diabetic macrovascular disease. Further development of …
The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes
F Iannantuoni, A M. de Marañon… - Journal of clinical …, 2019 - mdpi.com
Sodium–glucose co-transporter 2 inhibitors (iSGLT2) have been linked to a considerable
reduction in cardiovascular risk in patients with type 2 diabetes (T2D), but the precise …
reduction in cardiovascular risk in patients with type 2 diabetes (T2D), but the precise …
Empagliflozin improves cognitive impairment in frail older adults with type 2 diabetes and heart failure with preserved ejection fraction
P Mone, A Lombardi, J Gambardella, A Pansini… - Diabetes …, 2022 - Am Diabetes Assoc
OBJECTIVE To assess whether the sodium–glucose cotransporter 2 (SGLT2) inhibitor
empagliflozin improves cognitive impairment in frail older adults with diabetes and heart …
empagliflozin improves cognitive impairment in frail older adults with diabetes and heart …
Functional and clinical importance of SGLT2-inhibitors in frailty: from the kidney to the heart
SGLT2 (sodium-glucose cotransporter 2) enables glucose and sodium reabsorption in the
kidney. SGLT2-inhibitors (also known as gliflozins, which include canagliflozin …
kidney. SGLT2-inhibitors (also known as gliflozins, which include canagliflozin …
[HTML][HTML] Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission
Impaired cardiac microvascular function contributes to diabetic cardiovascular complications
although effective therapy remains elusive. Empagliflozin, a sodium-glucose cotransporter 2 …
although effective therapy remains elusive. Empagliflozin, a sodium-glucose cotransporter 2 …
The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering …
M Oelze, S Kröller-Schön, P Welschof, T Jansen… - PloS one, 2014 - journals.plos.org
Objective In diabetes, vascular dysfunction is characterized by impaired endothelial function
due to increased oxidative stress. Empagliflozin, as a selective sodium-glucose co …
due to increased oxidative stress. Empagliflozin, as a selective sodium-glucose co …
Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice
B Ganbaatar, D Fukuda, M Shinohara, S Yagi… - European Journal of …, 2020 - Elsevier
Recent studies reported cardioprotective effects of sodium glucose co-transporter 2 (SGLT2)
inhibitors; however, the underlying mechanisms are still obscure. Here, we investigated …
inhibitors; however, the underlying mechanisms are still obscure. Here, we investigated …
Acute and chronic effects of SGLT2 inhibitor empagliflozin on renal oxygenation and blood pressure control in nondiabetic normotensive subjects: a randomized …
A Zanchi, M Burnier, ME Muller… - Journal of the …, 2020 - Am Heart Assoc
Background The sodium/glucose cotransporter 2 inhibitor empagliflozin has cardiorenal
protective properties through mechanisms beyond glucose control. In this study we …
protective properties through mechanisms beyond glucose control. In this study we …